Interventions to improve follow-up of positive results on fecal blood tests: A systematic review

Annals of Internal Medicine

Volumn 167, Issue 8, 2017, Pages 565-575

  Selby, Kevin ^a   Baumgartner, Christine ^b   Levin, Theodore R ^c   Doubeni, Chyke A ^d   Zauber, Ann G ^e   Schottinger, Joanne ^f   Jensen, Christopher D ^a   Lee, Jeffrey K ^b   Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC;

COLONOSCOPY; FOLLOW UP; FUNDING; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; TOTAL QUALITY MANAGEMENT; AFTERCARE; COLORECTAL NEOPLASMS; OCCULT BLOOD; STATISTICAL BIAS; UTILIZATION;

AFTERCARE; BIAS (EPIDEMIOLOGY); COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; OCCULT BLOOD; PATIENT NAVIGATION;

EID: 85031847907     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-1361     Document Type: Review

References (61)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30. [PMID: 26742998] doi:10.3322/caac.21332
2. Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015;121: 2281-5. [PMID: 25763558] doi:10.1002/cncr.29336
3. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541-9. [PMID: 18479499] doi:10.1111/j.1572-0241.2008 .01875.x
4. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564-75. [PMID: 2730 4597] doi:10.1001/jama.2016.5989
5. Segnan N, Patnick J, von Karsa L. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Luxembourg City, Luxembourg: Publications Office of the European Union; 2010.
6. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014;106: dju032. [PMID: 24681602] doi:10.1093/jnci/dju032
7. Powell AA, Nugent S, Ordin DL, Noorbaloochi S, Partin MR. Evaluation of a VHA collaborative to improve follow-up after a positive colorectal cancer screening test. Med Care. 2011;49:897-903. [PMID: 21642875] doi:10.1097/MLR.0b013e3182204944
8. Paterson WG, Depew WT, Paré P, Petrunia D, Switzer C, Veldhuyzen van Zanten SJ, et al; Canadian Association of Gastroenterology Wait Time Consensus Group. Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol. 2006;20:411-23. [PMID: 16779459]
9. Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, et al. Consequences of increasing time to colonoscopy examination after positive result from fecal colorectal cancer screening test. Clin Gastroenterol Hepatol. 2016;14:1445-51. [PMID: 27211498] doi:10.1016/j.cgh.2016.05.017
10. 10. Gellad ZF, Almirall D, Provenzale D, Fisher DA. Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia. Dig Dis Sci. 2009;54:2497-502. [PMID: 19093199] doi:10 .1007/s10620-008-0653-8
11. 11. Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317:1631-41. [PMID: 28444278] doi:10 .1001/jama.2017.3634
12. Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, et al. Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006;49:1002-10. [PMID: 16673056]
13. 13. Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, et al; PROSPR consortium. Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25:344-50. [PMID: 26843520] doi:10 .1158/1055-9965.EPI-15-0470
14. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-71. [PMID: 8474513]
15. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecaloccult- blood test. Lancet. 1996;348:1467-71. [PMID: 8942774]
16. Zapka JM, Edwards HM, Chollette V, Taplin SH. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev. 2014;23:1965-73. [PMID: 25073625] doi:10.1158/1055-9965.EPI-14-0454
17. Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE, Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up? Arch Intern Med. 2011;171:249-56. [PMID: 20937917] doi:10.1001/archinternmed .2010.372
18. Turner B, Myers RE, Hyslop T, Hauck WW, Weinberg D, Brigham T, et al. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003;18:357-63. [PMID: 12795734]
19. McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, et al; PROSPR consortium. Follow-up of abnormal breast and colorectal cancer screening by race/ethnicity. Am J Prev Med. 2016;51:507-12. [PMID: 27132628] doi:10.1016/j.amepre.2016.03 .017
20. Choi KS, Lee HY, Jun JK, Shin A, Park EC. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008. J Gastroenterol Hepatol. 2012;27:1070-7. [PMID: 22004224] doi:10.1111/j .1440-1746.2011.06944.x
21. 21. Martin J, Halm EA, Tiro JA, Merchant Z, Balasubramanian BA, McCallister K, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130:93.e1-93. [PMID: 27591183] doi:10 .1016/j.amjmed.2016.07.028.
22. Bastani R, Yabroff KR, Myers RE, Glenn B. Interventions to improve follow-up of abnormal findings in cancer screening. Cancer. 2004;101:1188-200. [PMID: 15316914]
23. Dalton AR. Incomplete diagnostic follow-up after a positive colorectal cancer screening test: a systematic review. J Public Health (Oxf). 2017. [PMID: 28069989] doi:10.1093/pubmed/fdw147.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. [PMID: 19631508] doi:10.1016/j.jclinepi.2009.06.005
25. Improving followup of abnormal colon cancer screening tests. ClinicalTrials.gov: NCT00436137. Accessed at https://clinicaltrials .gov/ct2/show/study/NCT00436137 on 27 February 2017.
26. The effect of printed reminders on the use of colorectal cancer screening follow-up exams: a randomized controlled study. University Hospital Medical Information Network. 2014. Accessed at https: //upload.umin.ac.jp/cgi-open-bin/icdr-e/ctr-view.cgi?recptno=R000 009596 on 27 February 2017.
27. Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1217-37. [PMID: 27769517] doi:10.1053/j.gastro .2016.08.053
28. Liao A, Jeyalingam T, Saibil F. A46. Wait time for colonoscopy is reduced by email communication. Can J Gastroenterol Hepatol. 2016;2016:30-1.
29. Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. J Gen Intern Med. 2016;31: 1323-30. [PMID: 27412426]
30. Murphy DR, Wu L, Thomas EJ, Forjuoh SN, Meyer AN, Singh H. Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial. J Clin Oncol.2015;33:3560-7.[PMID:26304875]doi:10.1200/JCO.2015.61 .1301
31. Ratner S, Franks L, Colford C, Reuland DS, McGuirt BB, McMillan C, et al. Systematic tracking and follow up of abnormal cancer screening tests utilizing a social work care manager to improve patient safety in an academic primary care clinic. J Gen Intern Med. 2016;31:S909.
32. Fasoli R, Pace N, De Pretis G, Faitini K, Mastromauro M, Armelao F, et al. Cost-effectiveness of medical counselling in faecal occult blood-positive subjects. Experience of Trentino screening program. Dig Liver Dis. 2010;42:S68-9.
33. Stock D, Rabeneck L, Baxter NN, Paszat LF, Sutradhar R, Yun L, et al. Mailed participant reminders are associated with improved colonoscopy uptake after a positive FOBT result in Ontario's Colon- CancerCheck program. Implement Sci. 2015;10:35. [PMID: 2588 5531] doi:10.1186/s13012-015-0226-0
34. Powell AA, Gravely AA, Ordin DL, Schlosser JE, Partin MR. Timely follow-up of positive fecal occult blood tests strategies associated with improvement. Am J Prev Med. 2009;37:87-93. [PMID: 19524390] doi:10.1016/j.amepre.2009.05.013
35. Stock D, Rabeneck L, Baxter NN, Paszat LF, Sutradhar R, Yun L, et al. A centrally generated primary care physician audit report does not improve colonoscopy uptake after a positive result on a fecal occult blood test in Ontario's ColonCancerCheck program. Curr Oncol. 2017;24:47-51. [PMID: 28270725] doi:10.3747/co.24.3025
36. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol. 2010;63:513-23. [PMID: 19595577] doi:10.1016/j .jclinepi.2009.03.009
37. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-15. [PMID: 21247734] doi:10.1016/j.jclinepi.2010.07.017
38. Van Roosbroeck S, Hoeck S, Van Hal G. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies. Cancer Epidemiol. 2012;36:e317-24. [PMID: 22560885] doi:10.1016/j.canep .2012.04.003
39. Green BB, Anderson ML, Wang CY, Vernon SW, Chubak J, Meenan RT, et al. Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. J AmBoard Fam Med. 2014;27:789-95. [PMID: 25381076] doi:10.3122/jabfm.2014.06 .140125
40. Raich PC, Whitley EM, Thorland W, Valverde P, Fairclough D; Denver Patient Navigation Research Program. Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomarkers Prev. 2012;21:1629-38. [PMID: 23045537] doi:10.1158/1055-9965 .EPI-12-0513
41. Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004;38:375-81. [PMID: 15020170]
42. Grazzini G, Castiglione G, Isu A, Mantellini P, Rubeca T, Sani C, et al. Colorectal cancer screening by fecal occult blood testing: results of a population-based experience. Tumori. 2000;86:384-8. [PMID: 11130566]
43. Cha JM, Lee JI, Joo KR, Shin HP, Park JJ. Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patients with a positive fecal immunochemical test. Dig Dis Sci. 2011;56:3137-42. [PMID: 21688010] doi:10.1007/ s10620-011-1720-0
44. Rodger J, Steele RJ. Telephone assessment increases uptake of colonoscopy in a FOBT colorectal cancer-screening programme. J Med Screen. 2008;15:105-7. [PMID: 18573779] doi:10.1258/jms .2008.007093
45. Tran S, Jackson T, Adams J, Singh S, Lipscomb GR. Do patients who failed to attend their first bowel cancer screening clinic visit warrant further follow-up? Gut. 2010;59:A33.
46. Van Kleek E, Liu S, Conn LM, Hoadley A, Ho SB. Improving the effectiveness of fecal occult blood testing in a primary care clinic by direct colonoscopy referral for positive tests. J Healthc Qual. 2010; 32:62-9. [PMID: 20946427] doi:10.1111/j.1945-1474.2009.00071.x
47. Zorzi M, Giorgi Rossi P, Cogo C, Falcini F, Giorgi D, Grazzini G, et al; PARC Working Group. A comparison of different strategies used to invite subjects with a positive faecal occult blood test to a colonoscopy assessment. A randomised controlled trial in population-based screening programmes. Prev Med. 2014;65:70-6. [PMID: 24811759] doi:10.1016/j.ypmed.2014.04.022
48. Phillips-Angeles E, Song L, Hannon PA, Celedonia M, Stearns S, Edwards K, et al. Fostering partnerships and program success. Cancer. 2013;119 Suppl 15:2884-93. [PMID: 23868483] doi:10.1002/cncr .28157
49. Larson MF, Ko CW, Dominitz JA. Effectiveness of a provider reminder on fecal occult blood test follow-up. Dig Dis Sci. 2009;54: 1991-6. [PMID: 19255849] doi:10.1007/s10620-009-0751-2
50. Singh H, Wilson L, Petersen LA, Sawhney MK, Reis B, Espadas D, et al. Improving follow-up of abnormal cancer screens using electronic health records: trust but verify test result communication. BMC Med Inform Decis Mak. 2009;9:49. [PMID: 20003236] doi:10.1186/ 1472-6947-9-49
51. Humphrey LL, Shannon J, Partin MR, O'Malley J, Chen Z, Helfand M. Improving the follow-up of positive hemoccult screening tests: an electronic intervention. J Gen Intern Med. 2011;26:691-7. [PMID: 21327529] doi:10.1007/s11606-011-1639-3
52. Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, et al. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008;46:S91-6. [PMID: 18725839] doi:10.1097/MLR .0b013e31817946c8
53. Singh H, Kadiyala H, Bhagwath G, Shethia A, El-Serag H, Walder A, et al. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol. 2009; 104:942-52. [PMID: 19293786] doi:10.1038/ajg.2009.55
54. Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:41-5. [PMID: 22278157]
55. Sabatino SA, Lawrence B, Elder R, Mercer SL, Wilson KM, DeVinney B, et al; Community Preventive Services Task Force. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med. 2012;43:97-118. [PMID: 22704754] doi:10.1016/j.amepre.2012.04.009
56. Holden DJ, Jonas DE, Porterfield DS, Reuland D, Harris R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med. 2010;152:668-76. [PMID: 20388703] doi: 10.7326/0003-4819-152-10-201005180-00239
57. Lee JH, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R. Effect of patient navigation on time to diagnostic resolution among patients with colorectal cancer-related abnormalities. J Cancer Educ. 2014;29:144-50. [PMID: 24113902] doi:10.1007/s13187-013-0561-2
58. Wells KJ, Lee JH, Calcano ER, Meade CD, Rivera M, Fulp WJ, et al. A cluster randomized trial evaluating the efficacy of patient navigation in improving quality of diagnostic care for patients with breast or colorectal cancer abnormalities. Cancer Epidemiol Biomarkers Prev. 2012;21:1664-72. [PMID: 23045541] doi:10.1158/ 1055-9965.EPI-12-0448
59. Bensink ME, Ramsey SD, Battaglia T, Fiscella K, Hurd TC, McKoy JM, et al; Patient Navigation Research Program. Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program. Cancer. 2014;120:570-8. [PMID: 24166217] doi:10.1002/cncr.28438
60. Partin MR, Burgess DJ, Burgess JF Jr, Gravely A, Haggstrom D, Lillie SE, et al. Organizational predictors of colonoscopy follow-up for positive fecal occult blood test results: an observational study. Cancer Epidemiol Biomarkers Prev. 2015;24:422-34. [PMID: 2547 1345] doi:10.1158/1055-9965.EPI-14-1170
61. 61. Lee JK, Levin TR, Corley DA. The road ahead: what if gastroenterologists were accountable for preventing colorectal cancer? Clin Gastroenterol Hepatol. 2013;11:204-7. [PMID: 23432901] doi:10 .1016/j.cgh.2012.12.014